Skip to main content
main-content

Pioglitazone

News

09-13-2017 | Pioglitazone | EASD 2017 | News

TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea

 The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.

08-03-2017 | Ipragliflozin | News

Ipragliflozin and pioglitazone ‘equally beneficial’ for type 2 diabetes with NAFLD

Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.

Read more

Related topics

Superior

Related

Journal articles and book chapters

11-10-2016 | Type 2 diabetes | Review | Article

Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus

The authors discuss the prevalence of obesity and type 2 diabetes in children and adolescents and summarize published studies on the safety and effectiveness of antihyperglycemic medications in this population.

Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6

04-13-2016 | Medications | Review | Article

Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness

What are the trends in use for the newer medications in diabetes care? This review looks at the uptake, usage, and comparative effectiveness of TZDs, DPP-4 inhibitors, and GLP-1 RAs.

Ahuja V & Chou CH. Curr Diab Rep 2016;16:47. doi:10.1007/s11892-016-0744-4

12-01-2015 | Diabetic complications | Review | Article

Management of diabetes mellitus in patients with chronic kidney disease

Glycemic control is essential in delaying or preventing the onset of diabetic kidney disease. There are a number of glucose-lowering medications available, but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing.

Hahr AJ & Molitch ME. Clin Diabetes Endocrinol 2015;1:2. doi:10.1186/s40842-015-0001-9

image credits